


Palladium-IBM Cognos Integrated Brand Management Performance Blueprint



Introduction

The pharmaceutical industry faces numerous challenges, including patent expiration, generic competition, declining revenues, and—despite a considerable increase in research and development investment—a lack of new therapies. With the average cost of bringing a new product to market exceeding \$1 billion, pharmaceutical organizations are striving to achieve commercialization excellence by driving successful product launches and enhancing go-to-market productivity, all in the pursuit of maximizing brand value.

How effective is your brand management process? The answer to this question can have a significant bottom-line impact. Just a one-day improvement in the process of bringing a new product to market can net an additional \$1.1 million in daily prescription revenue for an average-performing drug¹.

The challenge is not limited to internal efficiencies alone. Working with external constituencies, including regulatory agencies and key opinion leaders (KOLs), is a critical success factor as well. To drive effective brand launches and ensure market acceptance, it is particularly important to communicate with KOLs in the medical community, both prior to and during a new product launch. Equally important are the processes for managing existing products on the market. Success depends on tapping a broad set of competencies, ranging from conducting late-stage trials to managing regulatory hurdles to informing the medical community about disease states.


This brings us to the critical role of the brand manager, as well as the therapeutic area manager. To make informed decisions, both must have a keen understanding of strategic objectives and be able to translate them into operational plans. With the right decision-making tools and capabilities, the brand and therapeutic manager can view the status of action plans, have real-time access to key performance indicators, and drill down into the operational details, by therapeutic area or geography, to isolate bottlenecks and take corrective action through flexible resource re-allocation.

The Palladium-IBM Cognos Integrated Brand Management Blueprint

Palladium, experts in performance management, has partnered with IBM to develop the *Palladium-IBM Cognos Integrated Brand Management*SM *Performance Blueprint* to address the complexity of managing a global pharmaceutical brand from strategic, operational, and financial perspectives.

This offering combines industry-tested performance management frameworks with proven enterprise performance management and planning tools. Delivered as a web-based solution, the *Blueprint* takes advantage of the powerful features of IBM Cognos® 8 Business Intelligence (BI) and the flexibility of IBM Cognos Enterprise Planning to provide access to meaningful information through strategy maps, corporate and divisional scorecards, and operational dashboards.

The Strategy Map framework defines strategic priorities



With real-time access to a brand's key performance indicators, a brand manager or therapeutic area manager can more effectively manage action plans and budgets, monitor cross-divisional processes, and ensure alignment with strategic objectives. The brand manager can take action by modifying and re-prioritizing the numerous project initiatives that impact a brand's performance in the market and reflect

them in the financial drivers of related budgets and plans. This, in turn, allows a pharmaceutical organization to create and refine a repeatable brand management process based on a single version of the truth—ensuring that decisions are made with the right information.

The following screen, a dashboard for a hypothetical therapy called Torsulin, allows a brand manager to view key metrics and initiatives at a glance, or drill down for more detail.

Welcome screen for Torsulin Brand Manager




© Copyright 2008 Paladium Group, Inc.

A simple click provides the brand manager with a comprehensive view of the key performance indicators (KPIs) necessary to ensure that both strategic and operational objectives are met. Furthermore, since stakeholders from different business areas must all contribute to the brand's success, the *Blueprint* also enables Medical Affairs, Marketing, and other critical functions and departments to collaborate using the tools and knowledge needed to successfully shape the market throughout the product life-cycle. This allows management to move from trial and error to a predictable process that links strategic priorities, investments, and business outcomes.



The Brand Management Dashboard provides a link between strategic priorities and operational KPIs

Finally, this *Blueprint* provides access to detailed planning and budgeting models, supported by automatic change notification, to enable faster and more effective resource allocation in areas such as KOL interactions and disease state awareness campaigns.



Resource allocation/re-allocation can be modeled, tracked, and consolidated based on real-time events instead of an annual planning process

Benefits and capabilities

The Blueprint allows users to understand how they are performing, drill-down into activity detail, identify problems, and take necessary financial and operational action. Key benefits include the ability to:

- Analyze and understand key drivers and metrics for a successful brand
- Identify process bottlenecks and bring a product to market as quickly as possible
- Enable top-down and bottom-up planning and management activities
- Understand the true impact of management decisions and investments.

IBM Cognos 8 BI software provides:

- Advanced scorecards and dashboards that are linked to strategic objectives
- A customized web-based portal for all brand management and therapeutic area management activities Role-based reports for individuals throughout the chain of command
- Integration with enterprise project management tools to allow for effective initiative management from a centralized console
- Detailed planning models to manage marketing initiatives, regulatory activities, and interactions with the medical community
- Structured event notification and status monitoring to ensure appropriate actions are taken when a decision is made.

The Palladium-IBM partnership brings together the consulting services, software, and support necessary to help pharmaceutical organizations attain significant competitive advantage. The *Blueprint* is the result of extensive collaboration and external validation, and the integration of applied domain expertise with a best-inclass technology platform.

The Palladium-IBM Cognos Integrated Brand Management Performance Blueprint is offered by the IBM Cognos Innovation Center for Performance Management. Performance Blueprints are pre-defined data, process, and policy models that help organizations speed their software deployments and drive faster return on investment. For more information on IBM Cognos solutions for pharmaceutical and life sciences companies, please visit www.cognos.com/lifesciences or email pharma@.com.

About Palladium Group

Palladium Group, Inc. helps the world's leading organizations measure and manage tomorrow's performance today by providing services and expertise in strategy, finance, and IT management. Through education, conferences, assessments, advisory services, consulting, and technology solutions Palladium helps clients successfully execute their strategies. Balanced Scorecard Collaborative, Palladium's education and certification division, manages the Balanced Scorecard Hall of Fame for Executing Strategy™. Palladium has 18 offices worldwide and an additional 17 affiliate offices throughout Europe, Latin America, Africa, and Asia-Pacific. Palladium currently has over 700 clients worldwide. For more information, please visit www.thepalladiumgroup.com

About the IBM Cognos Innovation Center For Performance Management

The IBM Cognos Innovation Center for Performance Management was established in North America and Europe to advance the understanding of proven planning and performance management techniques, technologies, and practices. The Innovation Center is dedicated to transforming routine performance management practices into "next practices" that help cut costs, streamline processes, boost productivity, enable rapid response to opportunity, and increase management visibility. Staffed globally by experts in planning, technology, and performance and strategy management, the Innovation Center partners with more than 600 IBM Cognos customers, academics, industry leaders, and others seeking to accelerate adoption, reduce risk, and maximize the impact of technology-enabled performance management practices. To join, visit www.cognos.com/innovationcenter.

About IBM Cognos BI and Performance Management

IBM Cognos business intelligence (BI) and performance management solutions deliver world-leading enterprise planning, consolidation and BI software, support and services to help companies plan, understand and manage financial and operational performance. IBM Cognos solutions bring together technology, analytical applications, best practices, and a broad network of partners to give customers an open, adaptive and complete performance solution. Over 23,000 customers in more than 135 countries around the world choose IBM Cognos solutions.

For further information or to reach a representative: www.ibm.com/cognos

Request a call

To request a call or to ask a question, go to www.ibm.com/cognos/contactus. An IBM Cognos representative will respond to your enquiry within two business days.



© Copyright IBM Corporation Corporation and Palladium Group, Inc. 2009

IBM Canada 3755 Riverside Drive Ottawa, ON, Canada K1G 4K9

Produced in Canada April 2009 All Rights Reserved.

IBM, and the IBM logo are trademarks of International Business Machines Corporation in the United States, other countries or both. For a complete list of IBM trademarks, see www.ibm.com/legal/copytrade.shtml.

Other company, product and service names may be trademarks or service marks of others.

References in this publication to IBM products or services do not imply that IBM intends to make them available in all countries in which IBM operates.

Any reference in this information to non-IBM Web sites are provided for convenience only and do not in any manner serve as an endorsement of those Web sites. The materials at those Web sites are not part of the materials for this IBM product and use of those Web sites is at your own risk.

Endnotes

 Statistics from the Tufts Center for the Study of Drug Development, September/October 2007 Tufts CSDD Impact Report.

IBM Cognos
Innovation Center
for Performance Management